Gland Pharma Ltd.
NSE: GLAND · Pharmaceuticals
Snapshot
Unlock Gland Pharma Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Gland Pharma Limited is a pharmaceutical company specialising in the development, manufacture, and marketing of complex injectable-focused generic liquid parenteral products. It operates primarily through a business-to-business model, offering a wide range of therapeutic categories including anti-infectives, anesthetics, and anti-coagulants.
Business Model
The company generates revenue through the sale of generic injectable products and the provision of contract development and manufacturing services. It serves global markets, including the United States, Europe, Canada, Australia, and India.
Growth Outlook
Growth is driven by the expansion of its complex injectable portfolio and the scaling of its contract development and manufacturing organisation (CDMO) capabilities. The company continues to leverage its established presence in regulated markets to capture demand for high-barrier-to-entry generic products.
Key Risks
- Regulatory Compliance. The company faces significant risks related to USFDA and other international regulatory inspections of its manufacturing facilities.
- Pricing Pressure. Intense competition in the generic injectable market can lead to price erosion and margin compression.
- Supply Chain Dependency. Reliance on external suppliers for active pharmaceutical ingredients (APIs) and key raw materials may impact production continuity.
- Geopolitical and Currency Risk. As a global exporter, the company is exposed to fluctuations in foreign exchange rates and changes in international trade policies.
Start your research today
Unlock AI insights, financials, peers and live data on Gland Pharma Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹6,725 Cr
TTM · consolidated
NET PROFIT
₹1,129 Cr
TTM · consolidated
EPS
₹68.51
TTM · consolidated
RETURN ON EQUITY
11.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.7%
TTM · consolidated
P/E
42.8x
Q1 FY27 · consolidated
EV/EBITDA
21.9x
Q1 FY27 · consolidated
EBITDA MARGIN
30.8%
TTM · consolidated
NET PROFIT MARGIN
17.6%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Gland Pharma Ltd.GLAND | ₹48,373 Cr | 42.80 | 21.85 | 17.6% | 30.8% | 11.6% | 15.7% | +55.5% |
Abbott India Ltd.ABBOTINDIA | ₹55,386 Cr | 35.69 | 25.20 | 8.1% | 31.5% | 35.5% | 45.4% | -19.0% |
Glaxosmithkline Pharmaceuticals Ltd.GLAXO | ₹50,112 Cr | 47.70 | 32.70 | 5.8% | 37.9% | 50.6% | 61.2% | +3.7% |
Ipca Laboratories Ltd.IPCALAB | ₹49,860 Cr | 38.07 | 20.90 | 10.6% | 23.7% | 18.3% | 19.4% | +46.8% |
Ajanta Pharmaceuticals Ltd.AJANTPHARM | ₹43,288 Cr | 38.14 | 25.77 | 20.2% | 29.1% | 27.3% | 34.4% | +33.2% |
Emcure Pharmaceuticals Ltd.EMCURE | ₹36,559 Cr | 36.13 | 18.90 | 18.4% | 20.6% | 21.7% | 27.3% | +40.6% |
As of Q1 FY27
Financials
Gland Pharma Ltd.
NSE: GLAND · Pharmaceuticals
Snapshot
Unlock Gland Pharma Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Gland Pharma Limited is a pharmaceutical company specialising in the development, manufacture, and marketing of complex injectable-focused generic liquid parenteral products. It operates primarily through a business-to-business model, offering a wide range of therapeutic categories including anti-infectives, anesthetics, and anti-coagulants.
Business Model
The company generates revenue through the sale of generic injectable products and the provision of contract development and manufacturing services. It serves global markets, including the United States, Europe, Canada, Australia, and India.
Growth Outlook
Growth is driven by the expansion of its complex injectable portfolio and the scaling of its contract development and manufacturing organisation (CDMO) capabilities. The company continues to leverage its established presence in regulated markets to capture demand for high-barrier-to-entry generic products.
Key Risks
- Regulatory Compliance. The company faces significant risks related to USFDA and other international regulatory inspections of its manufacturing facilities.
- Pricing Pressure. Intense competition in the generic injectable market can lead to price erosion and margin compression.
- Supply Chain Dependency. Reliance on external suppliers for active pharmaceutical ingredients (APIs) and key raw materials may impact production continuity.
- Geopolitical and Currency Risk. As a global exporter, the company is exposed to fluctuations in foreign exchange rates and changes in international trade policies.
Start your research today
Unlock AI insights, financials, peers and live data on Gland Pharma Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹6,725 Cr
TTM · consolidated
NET PROFIT
₹1,129 Cr
TTM · consolidated
EPS
₹68.51
TTM · consolidated
RETURN ON EQUITY
11.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.7%
TTM · consolidated
P/E
42.8x
Q1 FY27 · consolidated
EV/EBITDA
21.9x
Q1 FY27 · consolidated
EBITDA MARGIN
30.8%
TTM · consolidated
NET PROFIT MARGIN
17.6%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27